natgillin/translations-raw huggingface dataset:
CE/BZA has a minor influence on the ability to drive and use machines.
Kombinacija CE/BZA ima blag vpliv na sposobnost vožnje in upravljanja strojev.
- Jaundice or deterioration in liver function - Significant increase in blood pressure -New onset of migraine-type headache
- zlatenica ali poslabšanje delovanja jeter; - pomembno zvišanje krvnega tlaka; - nov napad migrenskega glavobola.
In clinical trials with bazedoxifene monotherapy, somnolence was reported as an adverse reaction, and patients should be advised on the potential effect on driving and using machines.
V kliničnih preskušanjih z monoterapijo z bazedoksifenom so poročali o zaspanosti kot neželenem učinku, zato je treba bolnice opozoriti na možne učinke na sposobnost vožnje in upravljanja strojev.
Risk ratio & 95% CI
Razmerje tveganja in 95 % IZ
Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only Hormone Replacement Therapy (HRT), which becomes apparent within 5 years of use and diminishes over time after stopping.
Epidemiološki podatki iz obširne metaanalize kažejo rahlo zvečano tveganje pri ženskah, ki uporabljajo samo estrogensko hormonsko nadomestno zdravljenje (HNZ), kar postane očitno po 5 letih uporabe in se po prenehanju sčasoma počasi zmanjšuje.
The following side effects have been observed when either conjugated oestrogens and/or bazedoxifene (the active ingredients in this medicine) has been used alone and may occur also with this medicine:
Naslednje neželene učinke so opazili pri jemanju konjugiranih estrogenov in/ali bazedoksifena (učinkovin v tem zdravilu) kot samostojnih zdravil, lahko pa se pojavijo tudi pri tem zdravilu:
The additional risk of ischaemic stroke over five years of use was assessed in the largest randomised trial in women without a uterus (WHI) from 50-59 years of age.
Dodatno tveganje za ishemično možgansko kap v petih letih uporabe so ocenili v največjem randomiziranem preskušanju pri ženskah brez maternice (WHI), starih od 50 do 59 let.
Do not store above 25C.
Shranjujte pri temperaturi do 25 C.
Uncommon: may affect 1 in 100 people • If you begin to get migraine-like headaches, or severe headaches
Občasni: pojavijo se lahko pri 1 od 100 bolnic • če se pojavijo glavoboli, podobni migreni, ali hudi glavoboli.
• increased risk of developing blood clots [see “Blood clots in a vein (thrombosis)”]
• zvečano tveganje za razvoj krvnih strdkov (glejte »Krvni strdki v veni (tromboza)«);
• if any of your close relatives has ever had a blood clot in the leg, lung or another organ
• če je kdorkoli v ožji družini imel krvni strdek v nogi, pljučih ali drugem organu;
Risk ratio
Razmerje tveganja
• A worsening of asthma
• poslabšanje astme;
Generally recognised risk factors for VTE include, use of oestrogens, older age, major surgery, prolonged immobilisation, obesity (BMI > 30 kg/m2), pregnancy/postpartum period, systemic lupus erythematosus (SLE), and cancer.
Splošno znani dejavniki tveganja za VTE vključujejo uporabo estrogenov, starost, večji kirurški poseg, dolgotrajno imobilizacijo, debelost (ITM > 30 kg/m2), nosečnost/poporodno obdobje, sistemski eritematozni lupus (SLE) in raka.
If so, you should see your doctor more often for check-ups:
Če to za vas drži, morate zdravnika obiskovati pogosteje:
Therapy should be discontinued in case a contraindication is discovered (e.g., venous thromboembolism, stroke, and pregnancy) and in the following situations:
Zdravljenje je treba prekiniti, če se odkrije kontraindikacija (npr. venska trombembolija, možganska kap in nosečnost) in v naslednjih primerih:
- Untreated endometrial hyperplasia.
- Nezdravljena hiperplazija endometrija.
- Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully monitored when being treated with CE/BZA.
- Estrogeni lahko povzročijo zastajanje tekočine v telesu, zato je treba bolnice z motenim delovanjem srca ali ledvic med zdravljenjem s CE/BZA skrbno spremljati.
Relief of symptoms occurring after menopause
Lajšanje simptomov, ki se pojavijo po menopavzi
• Blood clot in a vein at the back of the eye (retinal vein) which may lead to loss of vision
• krvni strdek v veni na zadnjem delu očesa (mrežnična vena), ki lahko povzroči izgubo vida;
• Erythema multiforme: symptoms may include skin rash with pink-red blotches especially on palms of hands or soles of feet which may blister.
• multiformni eritem: simptomi lahko vključujejo izpuščaj na koži z rožnato-rdečimi madeži, zlasti na dlaneh ali podplatih, kjer se lahko pojavijo tudi mehurji.
• Changes in your interest in sex (increased or decreased libido)
• spremembe v zanimanju za spolnost (zvečan ali zmanjšan libido);
The disposition of a single 20 mg dose of bazedoxifene was compared in women with hepatic impairment (Child-Pugh Class A [n=6], B [n=6], and C [n=6]) and subjects with normal hepatic function (n=18).
Farmakokinetiko enkratnega 20 mg odmerka bazedoksifena so primerjali pri ženskah z okvaro jeter (razred A [n = 6], B [n = 6] in C [n = 6] po Child-Pughovi lestvici) in preiskovankah z normalnim delovanjem jeter (n = 18).
- Women with pre-existing hypertriglyceridaemia should be followed closely during treatment with oestrogens, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.
- Ženske z obstoječo hipertrigliceridemijo je treba med zdravljenjem z estrogeni skrbno opazovati, ker so v redkih primerih pri zdravljenju bolnic v takem stanju z estrogenom poročali o velikem zvečanju trigliceridov v plazmi, ki je vodilo v pankreatitis.
* Taken from baseline incidence rates in developed countries Overall risk ratio.
* Na podlagi izhodiščne incidence v razvitih državah.
Bazedoxifene belongs to a group of non-hormonal medicines called selective estrogen receptor modulators (SERMs).
Bazedoksifen spada v skupino nehormonskih zdravil, imenovano selektivni modulatorji estrogenskega receptorja (SERM).
In clinical trials of up to 2 years duration in postmenopausal women with CE/BZA, cases of VTE have been reported (see section 4.8).
V kliničnih preskušanjih pri ženskah v postmenopavzi s CE/BZA, ki so trajala do 2 leti, so poročali o primerih VTE (glejte poglavje 4.8).
Million women study (Estradiol only arm) - estimated additional risk of breast cancer after 5 years use
Študija Million Women Study (skupina, ki je prejemala samo estradiol) - ocenjeno dodatno tveganje za raka dojke po 5 letih uporabe
• Medicines for tuberculosis (such as rifampicin, rifabutin);
• zdravila za zdravljenje tuberkuloze (kot sta rifampicin, rifabutin);
Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, collapse or even death.
Krvni strdki so lahko resni, ob prehodu v pljuča pa lahko povzročijo bolečine v prsnem košu, zasoplost, kolaps ali celo smrt.
Results from a clinical drug-drug interaction study conducted with CE/BZA and from interaction studies with CE or bazedoxifene monotherapy are summarised below.
Rezultati klinične študije medsebojnega delovanja, ki so jo izvedli s CE/BZA, in študij medsebojnega delovanja, ki so jih izvedli s CE ali monoterapijo z bazedoksifenom, so povzeti spodaj.
Physical (including pelvic and breast) examination should be guided by this and by the contraindications and precautions for use.
Telesni pregled (vključno z medeničnim predelom in dojkami) je treba opraviti glede na anamnezo, kontraindikacije in previdnostne ukrepe za uporabo.
On average, women with hepatic impairment showed a 4.3-fold increase in AUC compared with controls.
Pri ženskah z okvaro jeter je bila vrednost AUC povprečno 4,3-krat večja kot pri ženskah v kontrolni skupini.
The other ingredients are: lactose monohydrate, sucrose, sucrose monopalmitate, polydextrose (E1200, containing glucose and sorbitol) and maltitol liquid (see section 2), microcrystalline cellulose, powdered cellulose, hydroxypropylcellulose, hydroxyethylcellulose, magnesium stearate, ascorbic acid, hypromellose (E464), povidone (E1201), poloxamer 188, calcium phosphate, titanium dioxide (E171), macrogol (400), red iron oxide (E172), black iron oxide (E172) and propylene glycol (E1520).
Druge sestavine zdravila so: laktoza monohidrat, saharoza, saharoza monopalmitat, polidekstroza (E1200, vsebuje glukozo in sorbitol) in tekoči maltitol (glejte poglavje 2), mikrokristalna celuloza, celuloza v prahu, hidroksipropilceluloza, hidroksietilceluloza, magnezijev stearat, askorbinska kislina, hipromeloza (E464), povidon (E1201), poloksamer 188, kalcijev fosfat, titanov dioksid (E171), makrogol (400), rdeči železov oksid (E172), črni železov oksid (E172) in propilenglikol (E1520).
The active ingredients of CE are primarily the sulphate esters of estrone, equilin sulphates and 17α/β- estradiol.
Učinkovine CE so predvsem sulfatni estri estrona, ekvilinski sulfati in 17α/β-estradiol.
DUAVIVE alleviates these symptoms after menopause.
Zdravilo DUAVIVE lajša te simptome po menopavzi.
The risk of having a stroke is about 1.5 times higher in HRT users than in non-users.
Tveganje za možgansko kap je približno 1,5-krat večje pri uporabnicah HNZ kot pa pri ženskah, ki ne uporabljajo HNZ.
These tumours are known to occur in aged nonhuman primates and were considered spontaneous in the aged monkeys and irrelevant to humans.
Za te tumorje je znano, da se pojavljajo pri ostarelih živalskih primatih, in pri ostarelih opicah veljajo za spontane, torej te ugotovitve niso pomembne za ljudi.
Mean ± SD Steady-State Pharmacokinetic Parameters (n=24) Cmax (ng/mL)
Povprečje farmakokinetičnih parametrov ± SD v stanju dinamičnega ravnovesja (n = 24) Cmax (ng/ml)
Bazedoxifene does not induce or inhibit the activities of major CYP isoenzymes, and is unlikely to interact with co-administered medicinal products via CYP-mediated metabolism.
Bazedoksifen niti ne inducira niti ne zavira aktivnosti poglavitnih izoencimov CYP in je malo verjetno, da medsebojno deluje s sočasno uporabljenimi zdravili preko presnove, ki jo uravnava CYP.
If you take too many tablets you may have nausea (feel sick) or vomit.
Če vzamete preveč tablet, vam bo morda slabo ali boste bruhali.
Lactose, sucrose and glucose
Laktoza, saharoza in glukoza
• smoking
• kajenje;
You may need to stop taking DUAVIVE about 4 to 6 weeks before the operation, to reduce the risk of a blood clot (see Blood clots in a vein).
Za zmanjšanje tveganja za nastanek krvnega strdka boste morda morali prenehati z jemanjem zdravila DUAVIVE približno 4 do 6 tednov pred operacijo (glejte Krvni strdki v veni).
Effects on bone mineral density (BMD)
Učinki na mineralno gostoto kosti (MGK)
For the treatment of postmenopausal symptoms, CE/BZA should only be initiated for symptoms that adversely affect quality of life.
Kombinacija CE/BZA se lahko uporablja samo za zdravljenje postmenopavzalnih simptomov, ki negativno vplivajo na kakovost življenja.
When single doses of CE 0.625 mg/BZA 20 mg were administered with a high-fat meal, bazedoxifene Cmax was unaffected, but Area Under Curve (AUC) increased by approximately 25%.
Kadar so posamezne odmerke 0,625 mg CE/20 mg BZA dajali skupaj z obrokom z veliko vsebnostjo maščob, je bila vrednost Cmax za bazedoksifen nespremenjena, vendar se je vrednost površine pod krivuljo (AUC - area under the curve) zvečala za približno 25 %.
Patients with known thrombophilic states have an increased risk of VTE and hormone therapy may add to this risk.
Pri bolnicah z znanimi trombofiličnimi stanji je tveganje za VTE zvečano, hormonsko zdravljenje pa lahko to tveganje še zveča.
28 modified-release tablets
28 tablet s prirejenim sproščanjem
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before using this medicinal product.
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte z zdravnikom.
There is no experience in treating women with a premature menopause (due to ovarian failure or surgery) with DUAVIVE.
Izkušenj z zdravljenjem žensk z zgodnjo menopavzo (zaradi odpovedi jajčnikov ali kirurškega posega) z zdravilom DUAVIVE ni.
Oestrogen-only and bazedoxifene monotherapy increase the risk of blood clots in the veins (also called deep vein thrombosis, or DVT), especially during the first year of taking these medicines.
Samostojno zdravljenje samo z estrogenom ali z bazedoksifenom zveča tveganje za nastanek krvnih strdkov v venah (imenovanih tudi globoka venska tromboza ali GVT), zlasti v prvem letu jemanja zdravila.
Clinically, an increased metabolism of oestrogens may lead to decreased effect and changes in the uterine bleeding profile.
S kliničnega vidika lahko zvečana presnova estrogenov povzroči zmanjšan učinek in spremembe pri krvavitvah iz maternice.
BZA was not genotoxic or mutagenic in a battery of tests, including in vitro bacterial reverse mutation assay, in vitro mammalian cell forward mutation assay at the thymidine kinase (TK/-) locus in L5178Y mouse lymphoma cells, in vitro chromosome aberration assay in Chinese hamster ovary (CHO) cells, and in vivo mouse micronucleus assay.
BZA ni bil genotoksičen ali mutagen v nizu testov, vključno z bakterijskim testom reverzne mutacije in vitro, testu naprednih mutacij v celicah sesalcev na lokusu timidin-kinaze (TK/-) pri celicah mišjega limfoma L5178Y in vitro, testu kromosomskih aberacij pri celicah jajčnika kitajskega hrčka (CHO - Chinese hamster ovary) in vitro in testu mikronukleusa pri miših in vivo.
This change in BMD was similar to that shown with bazedoxifene 20 mg alone (+1.35%) and less than that seen with CE 0.45 mg/ medroxyprogesterone 1.5 mg (+2.58%) in the same study.
Ta sprememba MGK je bila podobna spremembi, ki so jo ugotovili pri samostojnem bazedoksifenu v odmerku 20 mg (+ 1,35 %), in manjša od spremembe, ki so jo v isti študiji opazili pri kombinaciji 0,45 mg CE/1,5 mg medroksiprogesterona (+ 2,58 %).
• Abrupt onset of abdominal pain and passage of bright red blood in the stool, with or without diarrhoea due to sudden blockage of an artery supplying the intestines (ischaemic colitis)
• nenaden pojav bolečine v trebuhu in izločanje svetlo rdeče krvi v blatu, z drisko ali brez nje, zaradi nenadne zamašitve arterije, ki dovaja kri v črevesje (ishemični kolitis);
In case of doubt, talk to your doctor before you take this medicine.
V primeru dvomov se posvetujte z zdravnikom, preden vzamete to zdravilo.
This relative risk is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women who use oestrogen therapy will increase with age (see section 4.4).
To relativno tveganje ni odvisno od starosti ali trajanja uporabe, vendar pa je izhodiščno tveganje močno odvisno od starosti, zato se skupno tveganje možganske kapi pri ženskah, ki uporabljajo zdravljenje samo z estrogenom, zveča s starostjo (glejte poglavje 4.4).
• increased risk of getting a oestrogen-sensitive cancer (such as having a mother, sister or grandmother who has had breast cancer)
• zvečano tveganje za razvoj od estrogenov občutljivega raka (npr. mati, sestra ali babica,
• Depression
• depresija;
Symptoms of overdose of oestrogen-containing medicinal products in adults and children may include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue; withdrawal bleeding may occur in females.
Simptomi prevelikega odmerjanja zdravil, ki vsebujejo estrogen, pri odraslih in otrocih lahko vključujejo navzeo, bruhanje, občutljivost dojk, omotico, bolečino v trebuhu ter dremavost/utrujenost; pri ženskah se lahko pojavijo odtegnitvene krvavitve.
Very common: may affect more than 1 in 10 people • Abdominal pain (stomach ache)
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnic • bolečina v trebuhu.
Endometrial hyperplasia and carcinoma
Hiperplazija endometrija in karcinom
The observation of benign, ovarian granulosa-cell tumours in female mice and rats administered bazedoxifene is a class effect of SERMs related to its pharmacology in rodents when treated during their reproductive lives, when their ovaries are functional and responsive to hormonal stimulation.
Opaženi benigni granulozocelularni tumorji na jajčnikih pri samicah miši in podgan, ki so prejemale bazedoksifen, so učinek skupine zdravil SERM, ki je povezan z njihovo farmakologijo pri samicah glodavcev, če jih prejemajo v rodni dobi, ko so njihovi jajčniki funkcionalni in se odzivajo na hormonsko stimulacijo.
Studies in rats with bazedoxifene have shown adverse effects on fertility (see section 5.3).
Študije z bazedoksifenom na podganah so pokazale škodljive vplive na plodnost (glejte poglavje 5.3).
If you stop taking DUAVIVE
Če ste prenehali jemati zdravilo DUAVIVE
The excess risk becomes apparent within a few years of use but returns to baseline within a few (at most five) years after stopping treatment.
Zvečano tveganje postane očitno po nekaj letih uporabe, vendar se vrne na izhodiščno vrednost v nekaj (največ petih) letih po prekinitvi zdravljenja.
Do not store above 25ºC.
Shranjujte pri temperaturi do 25 °C.
*no differentiation was made between ischaemic and haemorrhagic stroke.
* Niso razlikovali med ishemično in hemoragično možgansko kapjo.
The addition of bazedoxifene, acting as an oestrogen receptor antagonist in the uterus, greatly reduces the oestrogen-induced risk of endometrial hyperplasia in non-hysterectomised women.
Dodajanje bazedoksifena, ki deluje kot antagonist estrogenskih receptorjev v maternici, znatno zmanjša z estrogeni povezano tveganje hiperplazije endometrija pri nehisterektomiranih ženskah.
DUAVIVE is used in postmenopausal women who still have their uterus (womb) and have not had a natural period in the last 12 months.
Zdravilo DUAVIVE se uporablja pri ženskah po menopavzi, ki imajo še vedno maternico in v zadnjih 12 mesecih niso imele naravnega mesečnega perila.
- CE/BZA has not been studied in patients with impaired liver function (see sections 4.2 and 5.2) or history of cholestatic jaundice.
- Kombinacije CE/BZA pri bolnicah z okvarjenim delovanjem jeter (glejte poglavji 4.2 in 5.2) ali holestatskim ikterusom v anamnezi niso raziskovali.
- Undiagnosed genital bleeding.
- Nediagnosticirana krvavitev iz spolovil.
• A worsening of chorea (an existing neurological disorder characterised by involuntary spasmodic movements of the body)
• poslabšanje horeje (obstoječe nevrološke bolezni, za katero so značilni nenadzorovani spastični gibi telesa);
Women taking CE/BZA should not be taking progestins, additional oestrogens or selective oestrogen receptor modulators (SERMs).
Ženske, ki jemljejo CE/BZA, ne smejo jemati progestinov, dodatnih estrogenov ali selektivnih modulatorjev estrogenskih receptorjev (SERM - selective oestrogen receptor modulators).
CE/BZA pairs CE with the selective oestrogen receptor modulator (SERM), BZA, which is defined as a tissue selective oestrogen complex (TSEC).
Kombinacija CE/BZA vsebuje CE in selektivni modulator estrogenskih receptorjev (SERM - selective oestrogen receptor modulator) BZA, kar je opredeljeno kot tkivno selektivni estrogenski kompleks (TSEC - tissue selective oestrogen complex).
Each modified-release tablet contains 96.9 mg sucrose (includes 0.7 mg sucrose as sucrose monopalmitate), 62.9 mg lactose (as monohydrate), 0.2 mg maltitol liquid, 0.0176 mg glucose, and 0.0088 mg sorbitol
Ena tableta s prirejenim sproščanjem vsebuje 96,9 mg saharoze (vključuje 0,7 mg saharoze v obliki saharoze monopalmitata), 62,9 mg laktoze (v obliki monohidrata), 0,2 mg tekočega maltitola, 0,0176 mg glukoze in 0,0088 mg sorbitola.
Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones.
Čeprav sta ritonavir in nelfinavir znana kot močna zaviralca, pri sočasni uporabi s steroidnimi hormoni kažeta induktivne lastnosti.
This medicinal product contains lactose, sucrose, glucose (in polydextrose and maltitol liquid) and sorbitol (in polydextrose).
To zdravilo vsebuje laktozo, saharozo, glukozo (v obliki polidekstroze in tekočega maltitola) in sorbitol (v obliki polidekstroze).
Dementia; depression; mood altered; changes in libido
Psihiatrične motnje demenca, depresija, spremenjeno razpoloženje, spremembe libida razdražljivost
• fluid retention due to cardiac or kidney problems
• zastajanje tekočine v telesu zaradi težav s srcem ali ledvicami.
Conjugated oestrogens is a medicine that belongs to a group of medicines called hormone replacement therapy (HRT).
Konjugirani estrogeni spadajo v skupino zdravil, imenovanih hormonsko nadomestno zdravljenje (HNZ).
• A severe allergic reaction - symptoms may include sudden wheezing and chest pain or tightness, swelling of the eyelids, face, lips, mouth, tongue or throat, difficulty breathing, collapse
• huda alergijska reakcija; simptomi lahko vključujejo nenadno piskajoče dihanje in bolečino ali stiskanje v prsnem košu, otekanje vek, obraza, ustnic, ust, jezika ali grla, težko dihanje in kolaps;
Age range (years)
Razpon starosti (leta)
CE are soluble in water and are well-absorbed from the gastrointestinal tract after release from the medicinal product formulation.
CE so topni v vodi in se po sproščanju iz formulacije zdravila dobro absorbirajo iz prebavil.
• a disease affecting the eardrum and hearing (otosclerosis)
• bolezen, ki prizadene bobnič in sluh (otoskleroza);
CE/BZA is only for use in postmenopausal women, and is contraindicated in women who are or may become pregnant (see section 4.3).
Kombinacija CE/BZA je namenjena le za uporabo pri ženskah v postmenopavzi in je kontraindicirana pri nosečnicah ali ženskah v rodni dobi (glejte poglavje 4.3).
The modified-release tablets are provided in UPVC/Monochlorotrifluorethylene blister packs containing 28 tablets.
Tablete s prirejenim sproščanjem so na voljo v pretisnih omotih iz UPVC/monoklorotrifluoretilena, ki vsebujejo 28 tablet.
In the bazedoxifene osteoporosis treatment trial (mean age = 66.5 years), the VTE rate per 1,000 women-years through the 3-year study period was 2.86 in the bazedoxifene (20 mg) group and 1.76 in the placebo group and through the 5-year study period was 2.34 in the bazedoxifene 20 mg group and 1.56 in the placebo group.
V preskušanju zdravljenja osteoporoze z bazedoksifenom (povprečna starost = 66,5 let) je bil delež primerov VTE na 1.000 žensk-let v 3-letnem obdobju izvajanja študije 2,86 v skupini, ki je prejemala bazedoksifen (20 mg), in 1,76 v skupini, ki je prejemala placebo, v 5-letnem obdobju izvajanja študije pa 2,34 v skupini, ki je prejemala 20 mg bazedoksifena, in 1,56 v skupini, ki je prejemala placebo.
CE/BZA has not been studied in women over 75 years of age.
Kombinacije CE/BZA niso raziskovali pri ženskah, starejših od 75 let.
Observational studies have mostly reported a small increase in risk of having breast cancer diagnosed that is substantially lower than that found in users of oestrogen-progestagen combinations (see section 4.8).
V opazovalnih študijah so večinoma poročali o majhnem zvečanju tveganja za raka dojke, ki je bistveno manjše kot pri ženskah, ki so uporabljale kombinacije estrogena in progestogena (glejte poglavje 4.8).
Female rats were administered daily dosages of 0.3 to 30 mg/kg (0.15 to 14.6 times the human dose based on body surface area, mg /m2 [20 mg/kg dosage in humans is 12.3 mg/m2]) prior to and during mating with untreated males.
Samicam podgan so dajali dnevne odmerke od 0,3 do 30 mg/kg (0,15- do 14,6-kratni odmerek pri človeku glede na telesno površino, mg /m2 [odmerek 20 mg/kg pri človeku je 12,3 mg/m2]) pred parjenjem s samci, ki niso prejemali zdravila, in v času parjenja.
• A worsening of epilepsy (seizures)
• poslabšanje epilepsije (epileptični napadi);
Circulating oestrogens exist in a dynamic equilibrium of metabolic interconversions.
Estrogeni v obtoku obstajajo v dinamičnem ravnovesju presnovnih oblik, ki se spreminjajo ena v drugo.
Endometrial hyperplasia may be a precursor to endometrial cancer.
Hiperplazija endometrija je lahko prekurzor za raka endometrija.